For both ER-positive and ER-negative patients, 80 samples were randomly selected as a training set and the 100 genes most significantly associated with distant metastasis-free survival (DMFS) were used as a signature to predict tumor recurrence for the remaining ER-positive and ER-negative patients, respectively (Figure 1). This evidence concerns the gene ESR1 and neoplasm.